FDA: Ra-223 suspended until further notice

Due to manufacturing delays and shortage in supply, Ra-223, aka Xofigo, is currently not available, the FDA announced Oct. 7.

Neither the FDA nor the drug’s maker, Bayer Healthcare, have released an estimated date for when supply of Ra-223 will be restored.

Ra-223 dichloride injection is an oncologic therapeutic originally FDA-approved in May of last year for castration-resistant metastatic prostate cancer to the bone with no known visceral metastatic disease.